0001127602-17-019588.txt : 20170526 0001127602-17-019588.hdr.sgml : 20170526 20170526192050 ACCESSION NUMBER: 0001127602-17-019588 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170524 FILED AS OF DATE: 20170526 DATE AS OF CHANGE: 20170526 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bioverativ Inc. CENTRAL INDEX KEY: 0001681689 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813461310 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 225 2ND AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-663-4400 MAIL ADDRESS: STREET 1: 225 2ND AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DENNER ALEXANDER J CENTRAL INDEX KEY: 0001361754 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37859 FILM NUMBER: 17875328 MAIL ADDRESS: STREET 1: C/O SARISSA CAPITAL MANAGEMENT LP STREET 2: 660 STEAMBOAT ROAD, 3RD FLOOR CITY: GREENWICH STATE: CT ZIP: 06830 FORMER NAME: FORMER CONFORMED NAME: Denner Alexander J DATE OF NAME CHANGE: 20060504 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2017-05-24 0001681689 Bioverativ Inc. BIVV 0001361754 DENNER ALEXANDER J C/O BIOVERATIV INC. 225 SECOND AVENUE WALTHAM MA 02451 1 Common Stock 2017-05-24 4 P 0 340000 54.16 A 495000 I See footnotes Common Stock 2017-05-25 4 P 0 130000 54.9839 A 625000 I See footnotes Common Stock 2017-05-26 4 P 0 450000 57.2114 A 1075000 I See footnotes Common Stock 5001 D On May 24, 2017, each of Sarissa Capital Domestic Fund LP, a Delaware limited partnership ("Sarissa Domestic") and Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempt limited partnership ("Sarissa Offshore" and together with Sarissa Domestic, the "Sarissa Funds"), purchased an aggregate of 295,800 and 44,200 shares, respectively, of common stock of Bioverativ Inc. On May 25, 2017, each of Sarissa Domestic and Sarissa Offshore purchased an aggregate of 113,100 and 16,900 shares, respectively, of common stock of Bioverativ Inc. On May 26, 2017, each of Sarissa Domestic and Sarissa Offshore purchased an aggregate of 391,500 and 58,500 shares, respectively, of common stock of Bioverativ Inc. Full information regarding the number of shares purchased at each separate price will be provided upon request by the SEC staff, the issuer or a security holder of the issuer. This represents the weighted average price for shares purchased at a range between $54.0278 (low) and $54.2631 (high). This represents the weighted average price for shares purchased at a range between $54.9826 (low) and $54.9994 (high). This represents the weighted average price for shares purchased at a range between $57.1471 (low) and $57.5297 (high). Includes (i) 390,871 shares beneficially owned by Sarissa Domestic and (ii) 104,129 shares beneficially owned by Sarissa Offshore. Includes (i) 503,971 shares beneficially owned by Sarissa Domestic and (ii) 121,029 shares beneficially owned by Sarissa Offshore. Includes (i) 895,471 shares beneficially owned by Sarissa Domestic and (ii) 179,529 shares beneficially owned by Sarissa Offshore. Alexander Denner, Ph.D. is the Chief Investment Officer of Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), the investment advisor to the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. /s/ Alexander Denner 2017-05-26